Clinical characteristics of the CHOP-O (n = 17) and independent cohorts (n = 12) at the time of inclusion
| Clinical characteristics . | CHOP-O cohort, n = 17 . | Lund cohort, n = 12 . |
|---|---|---|
| n, mean (range; SD), or N (%) . | n, mean (range; SD), or N (%) . | |
| Age, y | ||
| n = | 14/17 | 12/12 |
| Mean (range; SD) | 65.0 (48.4-86.8; 12.5) | 66.6 (49.0-79.0; 9.1) |
| <60 | 4 (28.6) | 3 (25.0) |
| >60 | 10 (71.4) | 9 (75.0) |
| Sex | ||
| n = | 14/17 | 12/12 |
| Female | 4 (28.6) | 3 (25.0) |
| Male | 10 (71.4) | 9 (75.0) |
| ECOG performance status | ||
| n = | 14/17 | 12/12 |
| 0 | 8 (57.1) | 3 (25.0) |
| 1 | 3 (21.4) | 6 (50.0) |
| 2 | 1 (7.1) | 3 (25.0) |
| 3 | 2 (14.3) | 0 (0) |
| Rai stage | ||
| n = | 14/17 | 12/12 |
| Rai 0 | 4 (28.6) | 1 (8.3) |
| Rai I | 4 (28.6) | 1 (8.3) |
| Rai II | 4 (28.6) | 3 (25.0) |
| Rai III | 1 (7.1) | 0 (0) |
| Rai IV | 1 (7.1) | 7 (58.3) |
| Binet stage | ||
| n = | 14/17 | 12/12 |
| Binet A | 4 (28.6) | 4 (33.3) |
| Binet B | 7 (50.0) | 1 (8.3) |
| Binet C | 3 (21.4) | 7 (58.3) |
| Ann Arbor stage | ||
| n = | 13/17 | 12/12 |
| Ann Arbor I | 1 (7.7) | 0 (0) |
| Ann Arbor II | 3 (23.1) | 2 (16.7) |
| Ann Arbor III | 6 (46.2) | 2 (16.7) |
| Ann Arbor IV | 3 (23.1) | 8 (66.7) |
| IPI score | ||
| n = | 13/17 | 12/12 |
| 1 | 5 (38.5) | 1 (8.3) |
| 2 | 2 (15.4) | 2 (16.7) |
| 3 | 4 (30.8) | 4 (33.3) |
| 4 | 2 (15.4) | 5 (41.7) |
| Previous treatment | ||
| n = | 16/17 | 12/12 |
| 0 | 4 (25.0) | 5 (41.7) |
| 1 | 8 (50.0) | 1 (8.3) |
| >1 | 4 (25.0) | 6 (50.0) |
| Type of previous treatment | ||
| n = | 16/17 | 12/12 |
| FC | 4 (25) | 3 (25.0) |
| FCR | 6 (37.5) | 3 (25.0) |
| Alemtuzumab ± high-dose steroid | 2 (12.5) | 6 (50.0) |
| Chlorambucil ± rituximab | 1 (6.3) | 1 (8.3) |
| Rituximab | 2 (12.5) | 0 (0) |
| Other | 2 (12.5) | 8 (66.7) |
| B symptoms | ||
| n = | 14/17 | 12/12 |
| Yes | 11 (78.6) | 10 (83.3) |
| No. of extranodal sites | ||
| n = | 17/17 | 12/12 |
| 0 | 8 (47.1) | 4 (33.3) |
| 1 | 7 (41.2) | 8 (66.7) |
| >1 | 2 (11.8) | 0 (0) |
| Bulk in lymph node > 5 cm | ||
| n = | 14/17 | 12/12 |
| Yes | 6 (42.9) | 6 (50.0) |
| IgHV mutation status | ||
| Unmutated | 10 | 0 (0) |
| Mutated | 4 | 0 (0) |
| Failed or Not done | 3, Failed | 12 (100), Not done |
| LDH | ||
| n = | 14/17 | 12/12 |
| >1× ULN | 8 (57.1) | 5 (41.7) |
| >1.5× ULN | 3 (21.4) | 6 (50.0) |
| β2-microglobulin > ULN | ||
| n = | 12/17 | 1/12 |
| N (%) | 4 (33.3) | 1 (8.3) |
| TP53 disruption detected in clinical trial | ||
| n = | 17/17 | |
| N (%) | 8 (47.1) | |
| TP53 disruption detected in clinical setting: FISH | ||
| n = | 7/12 | |
| N (%) | 3 (42.8) | |
| MYC expression ≥20% | ||
| n = | 12/17 | 12/12 |
| N (%) | 6 (50.0) | Not done |
| EBV expression in tumor | ||
| n = | 16/17 | |
| N (%) | 1 (6.3) | |
| EBV expression in tumor: IHC | ||
| n = | 1/12 | |
| pos IHC | 0 (0) | |
| EBV screening by DNA in plasma or IgM serology | ||
| n = | 10/12 | |
| pos plasma EBV DNA or IgM serology | 1 (10) | |
| ABC type cell of origin | ||
| n = | 14/17 | 12/12 |
| N (%) | 14 (100) | Not done |
| Clinical characteristics . | CHOP-O cohort, n = 17 . | Lund cohort, n = 12 . |
|---|---|---|
| n, mean (range; SD), or N (%) . | n, mean (range; SD), or N (%) . | |
| Age, y | ||
| n = | 14/17 | 12/12 |
| Mean (range; SD) | 65.0 (48.4-86.8; 12.5) | 66.6 (49.0-79.0; 9.1) |
| <60 | 4 (28.6) | 3 (25.0) |
| >60 | 10 (71.4) | 9 (75.0) |
| Sex | ||
| n = | 14/17 | 12/12 |
| Female | 4 (28.6) | 3 (25.0) |
| Male | 10 (71.4) | 9 (75.0) |
| ECOG performance status | ||
| n = | 14/17 | 12/12 |
| 0 | 8 (57.1) | 3 (25.0) |
| 1 | 3 (21.4) | 6 (50.0) |
| 2 | 1 (7.1) | 3 (25.0) |
| 3 | 2 (14.3) | 0 (0) |
| Rai stage | ||
| n = | 14/17 | 12/12 |
| Rai 0 | 4 (28.6) | 1 (8.3) |
| Rai I | 4 (28.6) | 1 (8.3) |
| Rai II | 4 (28.6) | 3 (25.0) |
| Rai III | 1 (7.1) | 0 (0) |
| Rai IV | 1 (7.1) | 7 (58.3) |
| Binet stage | ||
| n = | 14/17 | 12/12 |
| Binet A | 4 (28.6) | 4 (33.3) |
| Binet B | 7 (50.0) | 1 (8.3) |
| Binet C | 3 (21.4) | 7 (58.3) |
| Ann Arbor stage | ||
| n = | 13/17 | 12/12 |
| Ann Arbor I | 1 (7.7) | 0 (0) |
| Ann Arbor II | 3 (23.1) | 2 (16.7) |
| Ann Arbor III | 6 (46.2) | 2 (16.7) |
| Ann Arbor IV | 3 (23.1) | 8 (66.7) |
| IPI score | ||
| n = | 13/17 | 12/12 |
| 1 | 5 (38.5) | 1 (8.3) |
| 2 | 2 (15.4) | 2 (16.7) |
| 3 | 4 (30.8) | 4 (33.3) |
| 4 | 2 (15.4) | 5 (41.7) |
| Previous treatment | ||
| n = | 16/17 | 12/12 |
| 0 | 4 (25.0) | 5 (41.7) |
| 1 | 8 (50.0) | 1 (8.3) |
| >1 | 4 (25.0) | 6 (50.0) |
| Type of previous treatment | ||
| n = | 16/17 | 12/12 |
| FC | 4 (25) | 3 (25.0) |
| FCR | 6 (37.5) | 3 (25.0) |
| Alemtuzumab ± high-dose steroid | 2 (12.5) | 6 (50.0) |
| Chlorambucil ± rituximab | 1 (6.3) | 1 (8.3) |
| Rituximab | 2 (12.5) | 0 (0) |
| Other | 2 (12.5) | 8 (66.7) |
| B symptoms | ||
| n = | 14/17 | 12/12 |
| Yes | 11 (78.6) | 10 (83.3) |
| No. of extranodal sites | ||
| n = | 17/17 | 12/12 |
| 0 | 8 (47.1) | 4 (33.3) |
| 1 | 7 (41.2) | 8 (66.7) |
| >1 | 2 (11.8) | 0 (0) |
| Bulk in lymph node > 5 cm | ||
| n = | 14/17 | 12/12 |
| Yes | 6 (42.9) | 6 (50.0) |
| IgHV mutation status | ||
| Unmutated | 10 | 0 (0) |
| Mutated | 4 | 0 (0) |
| Failed or Not done | 3, Failed | 12 (100), Not done |
| LDH | ||
| n = | 14/17 | 12/12 |
| >1× ULN | 8 (57.1) | 5 (41.7) |
| >1.5× ULN | 3 (21.4) | 6 (50.0) |
| β2-microglobulin > ULN | ||
| n = | 12/17 | 1/12 |
| N (%) | 4 (33.3) | 1 (8.3) |
| TP53 disruption detected in clinical trial | ||
| n = | 17/17 | |
| N (%) | 8 (47.1) | |
| TP53 disruption detected in clinical setting: FISH | ||
| n = | 7/12 | |
| N (%) | 3 (42.8) | |
| MYC expression ≥20% | ||
| n = | 12/17 | 12/12 |
| N (%) | 6 (50.0) | Not done |
| EBV expression in tumor | ||
| n = | 16/17 | |
| N (%) | 1 (6.3) | |
| EBV expression in tumor: IHC | ||
| n = | 1/12 | |
| pos IHC | 0 (0) | |
| EBV screening by DNA in plasma or IgM serology | ||
| n = | 10/12 | |
| pos plasma EBV DNA or IgM serology | 1 (10) | |
| ABC type cell of origin | ||
| n = | 14/17 | 12/12 |
| N (%) | 14 (100) | Not done |
n = number of assessed subjects; N = number of assessed subjects within each group.
ABC, activated B-cells; EBV, Epstein-Barr virus; ECOG, Eastern Cooperative Oncology Group; FC, fludarabine, cyclophosphamide; FCR, fludarabine, cyclophosphamide, rituximab; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; IgHV, immunoglobulin heavy chain; IPI, International Prognostic Index; LDH, lactate dehydrogenase; SD, standard deviation; ULN, upper limit of normal.